A malignus melanóma prognosztikus és prediktív markerei

Translated title of the contribution: Prognostic and predictive markers of malignant melanoma

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Malignant melanoma biologically can be divided into non-metastatic and metastatic forms which cannot be predicted precisely using classical clinicopathological parameters, therefore studies on novel genetic or protein markers are abundant in the literature. These studies did not result in clinically useful markers because mostly ignored the results of studies on the genetic basis of metastatic potential of malignant melanoma. Accordingly, the list of promising novel markers is short (BCL2, CDK2, MART-1, OPN). Similar to other solid malignancies, introduction of targeted therapy into clinical practice of melanoma turned the attention toward the genetic basis of resistance to chemo- and targeted therapies. These novel data could lead to the development of molecular diagnostics which can help in designing more effective therapeutic strategies of malignant melanoma.

Original languageHungarian
Pages (from-to)79-83
Number of pages5
JournalMagyar Onkologia
Volume57
Issue number2
Publication statusPublished - 2013

Fingerprint

Melanoma
Molecular Pathology
Therapeutics
Neoplasms
Proteins

ASJC Scopus subject areas

  • Oncology

Cite this

A malignus melanóma prognosztikus és prediktív markerei. / Rásó, E.; Tamás, Barbai; Györffy, B.; Tímár, J.

In: Magyar Onkologia, Vol. 57, No. 2, 2013, p. 79-83.

Research output: Contribution to journalArticle

@article{0b51c75c6b6a4af8938405bd5f2acfd1,
title = "A malignus melan{\'o}ma prognosztikus {\'e}s predikt{\'i}v markerei",
abstract = "Malignant melanoma biologically can be divided into non-metastatic and metastatic forms which cannot be predicted precisely using classical clinicopathological parameters, therefore studies on novel genetic or protein markers are abundant in the literature. These studies did not result in clinically useful markers because mostly ignored the results of studies on the genetic basis of metastatic potential of malignant melanoma. Accordingly, the list of promising novel markers is short (BCL2, CDK2, MART-1, OPN). Similar to other solid malignancies, introduction of targeted therapy into clinical practice of melanoma turned the attention toward the genetic basis of resistance to chemo- and targeted therapies. These novel data could lead to the development of molecular diagnostics which can help in designing more effective therapeutic strategies of malignant melanoma.",
keywords = "Genetic markers, Melanoma, Prognosis, Therapy resistance",
author = "E. R{\'a}s{\'o} and Barbai Tam{\'a}s and B. Gy{\"o}rffy and J. T{\'i}m{\'a}r",
year = "2013",
language = "Hungarian",
volume = "57",
pages = "79--83",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - A malignus melanóma prognosztikus és prediktív markerei

AU - Rásó, E.

AU - Tamás, Barbai

AU - Györffy, B.

AU - Tímár, J.

PY - 2013

Y1 - 2013

N2 - Malignant melanoma biologically can be divided into non-metastatic and metastatic forms which cannot be predicted precisely using classical clinicopathological parameters, therefore studies on novel genetic or protein markers are abundant in the literature. These studies did not result in clinically useful markers because mostly ignored the results of studies on the genetic basis of metastatic potential of malignant melanoma. Accordingly, the list of promising novel markers is short (BCL2, CDK2, MART-1, OPN). Similar to other solid malignancies, introduction of targeted therapy into clinical practice of melanoma turned the attention toward the genetic basis of resistance to chemo- and targeted therapies. These novel data could lead to the development of molecular diagnostics which can help in designing more effective therapeutic strategies of malignant melanoma.

AB - Malignant melanoma biologically can be divided into non-metastatic and metastatic forms which cannot be predicted precisely using classical clinicopathological parameters, therefore studies on novel genetic or protein markers are abundant in the literature. These studies did not result in clinically useful markers because mostly ignored the results of studies on the genetic basis of metastatic potential of malignant melanoma. Accordingly, the list of promising novel markers is short (BCL2, CDK2, MART-1, OPN). Similar to other solid malignancies, introduction of targeted therapy into clinical practice of melanoma turned the attention toward the genetic basis of resistance to chemo- and targeted therapies. These novel data could lead to the development of molecular diagnostics which can help in designing more effective therapeutic strategies of malignant melanoma.

KW - Genetic markers

KW - Melanoma

KW - Prognosis

KW - Therapy resistance

UR - http://www.scopus.com/inward/record.url?scp=84887473191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887473191&partnerID=8YFLogxK

M3 - Article

C2 - 23795352

AN - SCOPUS:84887473191

VL - 57

SP - 79

EP - 83

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 2

ER -